Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven ...
Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion ...
Systemic inflammation research occupies a pivotal position at the intersection of immunology, metabolism, and disease pathogenesis. Recent advances have ...
The expanding use of immune checkpoint inhibitors (ICIs) has increased immune‑related hepatotoxicity (ChILI). Despite major guidelines, no standardized treatment consensus exists. Key controversies ...
Preview REIT earnings season: forecasts, key trends, IPO/M&A signals, and sector winners/laggards amid rate volatility. Read ...
Background Sex-based differences in immune response are well established, but whether men and women derive comparable benefit ...
HIV-1 envelope glycoprotein (Env), a gp120–gp41 trimer, undergoes coordinated conformational changes that drive membrane fusion and allow immune evasion by transiently concealing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results